Drugs » CINNARIZIN-PHARMA


Product name:    CINNARIZIN-PHARMA

Cinarizine Pharma 25 mg tablets
Product name: Cinarizin Pharma
Each tablet contains : Cinarizine 25 mg

Drug form: tablets
Pharmaceutical therapeutical classification:
Group : Antivertiginous medication
АТС (Anatomical therapeutical Classification) code: N 07CA 02
Instructions for use: Supporting treatment in case of symptoms of labyrinth disturbance like dizziness, tinnitus, pathologic nystagmus, nausea and vomiting. 

Read more:
Please, read this information carefully before use.
Read carefully the leaflet before administrartion of Cinnarizin!

PATIENT`S INFORMATION SHEET


CINNARIZIN 25 mg tablets

 

СOMPOSITION
Each tablet CINNARIZIN contains the medicinal substance Cinnarizine 25 mg and the following auxiliary substances: Lactose monohydrate, Colloidal silicon dioxide, Magnesium stearate, Povidone K25, Wheat starch and talc.

PHARMACEUTIC FORM
Cinnarizin is offered as plain tablets. It is linked  to the pharmacological groups: antivertiginous agents (ATC code N07C A 02).

INDICATIONS OF USAGE
Cinnarizin is used for treatment of  the following diseases and symptoms:

Instructions for use: Supporting treatment in case of symptoms of labyrinth disturbance like dizziness, tinnitus, pathologic nystagmus, nausea and vomiting.  

CONTRAINDICATION

Cinnarizin should not be taken in the following cases:
• When data for hypersensitivity to the preparation are available;
• At tremor or such neurological diseases as Parkinsonian syndrome;
• When data for depression are available.

Administaration during pregnancy and lactation
Cinnarizin is administered during pregnancy and lactation only on physician’s prescription and under physician’s control.

Influence upon ability to drive and operate machines
In some patients Cinnarizin may exert influence on  the active attention and reflexes. So, it should be used cautiously by patients working as drivers and machine operators due to  the above mentioned influence of Cinnarizin.
 

Interaction with other drugs and foods

In cases, when simultaneous administration of Cinnarizin and other medicinal preparations is necessary, see your doctor. Cinnarizin may increase the suppressing action of analgesics, soporific drugs, anesthetics, alcohol, etc. on the central nervous system.


Precautions

In some patients, in the beginning of the treatment, the prescribed dosage of Cinnarizin may cause dizziness, feeling of weakness, decrease of blood pressure. In such cases, it is necessary to see your doctor who will change the preparation"s dosage.


Adverse drug  reactions

The drug is usually well tolerated  by  patients. But as any other drug, Cinnarizin may cause adverse reactions in particular cases. Some disorders like drowsiness, dizziness, unpleasant abdominal sensations may appear in the beginning of the treatment. These symptoms do not require stopping the treatment. Skin eruptions, itching or other manifestations of hypersensitivity to the preparation may be observed very rarely.
After very prolonged treatment and in elder patients, Cinnarizin may cause disturbances of motor activity, and in particular cases, appearance of tremor and increased muscular tone.
In such cases, it is necessary to consult your doctor immediately.
At prolonged treatment with this preparation, there is a risk of gaining body weight.


DOSAGE AND ADMINISTRATION

Cinnarizin tablets are applied orally and intended for adults. Food does not exert vital influence on the action of the preparation.
The appropriate dosage is determined in every specific case by a physician. Usually 1 to 3 tablets three times daily are prescribed depending on the disease or patient’s state.
Long treatment is needed. Depending on observed healing effect, the treatment may continue up to some months.

Over dosage

In case of  carelessly taking a considerably higher dose than the prescribed and appearance of symptoms of drowsiness, vomiting, muscle weakness, tremor, it is necessary to search for  medical assistance.
Storage conditions and expiry date.
Keep the preparation at temperature not exceeding 25 C.
The expiry date of  the preparation is shown on the pack.
Avoid using the medicinal preparation after its expiry date!
Keep the medicinal preparation  out  of children"s reach!

MANIFACTURER AND HOLDER OF THE USE PERMIT
«PHARMA» PLC
the town of DUPNITSA,  «Neofit Rilsky» 13 street

DATE OF THE LAST CORRECTION OF THE TEXT:  Аugust, 2006 
 

All rights reserved 2008